BMS, KineMed Extend Alzheimer’s Pact

Bristol-Myers Squibb and KineMed, Inc. have extended their research collaboration in the area of Alzheimer’s disease and other neurodegenerative conditions. Under the extension, BMS has non-exclusive license to KineMed’s technologies to identify and characterize biomarkers for Alzheimer’s disease in cerebrospinal fluid.

“Understanding what is going on in the living brain is key to drug development in neurodegenerative diseases. We can measure fundamental brain processes in a living person that have never been measured before. KineMed is enabling research on potential treatments that address the causes, rather than the symptoms, of disease,” said David Fineman, president and chief executive officer of KineMed, Inc.

“Quantifying the dynamics of causative pathogenic processes such as neuronal transport gives pharma companies a tremendous advantage in monitoring drug efficacy,” commented Marc Hellerstein, M.D., Ph.D., head of KineMed’s Scientific Advisory Board and Calloway Chair Professor at UC Berkeley and Professor of Medicine at UCSF School of Medicine.